Ketamine: A Promising Treatment for Depression—or a Drug That Deserves More Caution?
Ketamine has been getting a lot of attention lately.
Some of that attention is positive. Ketamine can improve severe depressive symptoms remarkably quickly in certain patients, including people who have not responded to traditional antidepressants. Researchers are also studying it for anxiety, PTSD, chronic pain, and other difficult-to-treat conditions.
But the headlines have also highlighted the other side of ketamine: misuse, dependence, unregulated online prescribing, dissociation, bladder injury, and other complications associated particularly with frequent or unsupervised use.
Both sides of the story are important.
Ketamine is neither a miracle longevity drug nor simply a dangerous recreational substance. It is a legitimate medication with unusual pharmacology, meaningful therapeutic potential, and real risks.
The question is where it actually belongs in medicine.
What is ketamine?
Ketamine was originally developed as an anesthetic.
At higher doses, it can produce profound sedation and dissociation while preserving certain protective airway reflexes, making it useful in anesthesia and emergency medicine.
It has been used medically for decades.
What changed more recently was the discovery that much lower doses of ketamine can produce rapid antidepressant effects.
That was surprising because conventional antidepressants often take several weeks to produce noticeable improvement.
Ketamine sometimes begins affecting depressive symptoms within hours or days.
That fundamentally changed the way researchers began thinking about depression.
Ketamine works differently from traditional antidepressants
Most traditional antidepressants influence neurotransmitters such as serotonin, norepinephrine, or dopamine.
Ketamine primarily acts on a different signaling system involving glutamate, the brain's major excitatory neurotransmitter.
Its best-known action is blocking the NMDA receptor.
That initiates downstream changes involving other glutamate receptors, particularly AMPA receptors, and signaling pathways associated with BDNF, mTOR, and synaptic plasticity. These pathways appear to help brain cells strengthen and reorganize connections that may be impaired during chronic stress and depression. PubMed
This is one reason ketamine is sometimes described as a treatment that creates a temporary period of increased neuroplasticity.
That does not mean ketamine permanently “rewires the brain.”
It means the brain may temporarily become more capable of changing certain patterns of connectivity and behavior.
That distinction is important.
Ketamine and depression
Depression is where the evidence for ketamine is strongest.
Intravenous ketamine has been studied extensively as an off-label treatment for treatment-resistant depression, meaning depression that has not adequately responded to conventional therapies.
One of the most distinctive features is speed.
A patient who has struggled with severe depression for months or years may sometimes experience meaningful improvement shortly after treatment.
That does not happen for everyone, and the effects can fade without additional treatment, but the rapid response has made ketamine particularly important in psychiatry.
More recent research continues to support ketamine and its related medication esketamine as rapid-acting treatments for treatment-resistant depression, although the magnitude and durability of benefit vary considerably from patient to patient. PubMed
Ketamine and esketamine are not exactly the same thing
This distinction often gets lost.
Traditional ketamine is a mixture of two mirror-image molecules.
One of those molecules is esketamine, sometimes called S-ketamine.
Ketamine itself is FDA-approved as an anesthetic. It is not FDA-approved for depression or another psychiatric disorder, although physicians may prescribe or administer it off-label when clinically appropriate. U.S. Food and Drug Administration
Esketamine is different.
The intranasal formulation Spravato is FDA-approved for adults with treatment-resistant depression. As of the updated FDA labeling, it can be used as monotherapy or together with an oral antidepressant for treatment-resistant depression. It is also approved, together with an oral antidepressant, for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. Access Data
So when someone says they are receiving “ketamine therapy,” it is worth asking exactly what they are receiving.
Why the rapid antidepressant effect matters
One of the frustrations of severe depression is that conventional treatments can take time.
A medication may require several weeks before we know whether it works.
Ketamine's faster action can be clinically valuable, particularly when symptoms are severe and other treatments have failed.
It may also improve function, motivation, and quality of life in some patients, not simply scores on a depression questionnaire. Current research is increasingly evaluating these broader outcomes. PubMed
But ketamine should not be thought of as a guaranteed reset.
Some patients respond dramatically.
Others improve modestly.
Some do not respond.
And for many responders, the effect is not permanent.
What about suicidal thoughts?
This is one of the most clinically important areas of ketamine research.
Multiple trials have found that ketamine can produce a rapid reduction in suicidal thoughts, sometimes within the first day after treatment. A recent meta-analysis of randomized trials also found short-term reductions in suicidal ideation compared with an active control. PubMed
This potentially makes ketamine valuable in certain acute psychiatric situations.
But there is an important regulatory distinction.
The FDA label for Spravato specifically states that its effectiveness in preventing suicide or reducing suicidal behavior itself has not been established. Improvement after treatment also does not eliminate the need for hospitalization when hospitalization is clinically appropriate. Access Data
So ketamine is not a substitute for comprehensive suicide-risk management.
It can be one component of treatment.
What about anxiety?
The evidence for anxiety is promising but less established than it is for depression.
Studies have evaluated ketamine in people with difficult-to-treat anxiety disorders and in patients with depression who also have substantial anxiety symptoms.
A recent systematic review found signals of benefit across several anxiety-related populations, but the evidence remains heterogeneous, with relatively few studies specifically designed around primary anxiety disorders. PubMed
I would therefore not consider ketamine a routine first-line treatment for generalized anxiety or panic disorder.
Psychotherapy, particularly cognitive behavioral therapy, lifestyle interventions, and conventional medications have much larger bodies of long-term evidence.
Ketamine may have a role when symptoms are severe, refractory, or occur alongside treatment-resistant depression.
PTSD is another area of interest
Post-traumatic stress disorder is one of the more intriguing emerging applications.
Several clinical trials have found reductions in PTSD symptoms after ketamine infusions, sometimes relatively quickly.
However, the evidence is inconsistent.
A 2025 systematic review of randomized trials found meaningful benefit in some studies but not all, while earlier meta-analyses also suggested improvement but emphasized substantial differences between trials. PubMed
There is also growing interest in combining ketamine with psychotherapy.
The theory is that ketamine's temporary effect on neuroplasticity may create a period during which psychotherapy can have greater impact.
That is an appealing idea, but the quality of the evidence is still uneven. A 2026 analysis of ketamine-assisted psychotherapy for PTSD found promising results, but many of the included studies were considered low quality. PubMed
So I would consider this an evolving field rather than established standard therapy.
Other psychiatric conditions
Researchers are also studying ketamine for obsessive-compulsive disorder, bipolar depression, substance use disorders, eating disorders, and other psychiatric illnesses.
There are interesting early signals.
A systematic review examining ketamine across psychiatric disorders reported possible improvements in PTSD and OCD and suggested potential benefit in some alcohol-use-disorder studies. But the number of high-quality randomized trials remains limited. PubMed
This is an important recurring theme with ketamine.
There are many conditions where the mechanism is compelling and early studies are positive.
That is not the same thing as having enough evidence for routine treatment.
Ketamine and chronic pain
Ketamine also has analgesic properties.
NMDA receptors are involved in pain sensitization, which is one reason ketamine has been used for certain severe or refractory pain syndromes.
This includes some forms of neuropathic pain and complex regional pain syndrome.
However, the chronic-pain literature is more uncertain than many ketamine clinics imply.
A 2025 Cochrane review found that the evidence supporting ketamine for chronic non-cancer pain remained low or very low certainty, with no clear evidence of sustained benefit across the available trials. PubMed
A more recent clinical review concluded that ketamine may provide useful short-term analgesia in selected patients with severe refractory pain, particularly neuropathic pain, but emphasized the lack of good long-term data. PubMed
So again, ketamine may be useful.
But it is generally not a first-line chronic-pain treatment.
What does ketamine feel like?
At psychiatric doses, ketamine can produce altered perception.
People may describe feeling:
detached from their body,
as though time has changed,
dreamlike,
emotionally distant from thoughts,
or unusually introspective.
This is called dissociation.
Some people find the experience neutral or even therapeutic.
Others find it frightening or uncomfortable.
Dissociation is not necessarily the mechanism responsible for the antidepressant benefit, and a more intense subjective experience does not necessarily mean someone will have a better therapeutic response.
Ketamine therapy should not be approached as simply trying to produce the strongest possible psychedelic experience.
The risks are real
One of the reasons ketamine has generated negative headlines is that its therapeutic potential has expanded faster than our understanding of long-term use.
Short-term side effects can include dizziness, nausea, sedation, increased blood pressure, perceptual changes, impaired coordination, anxiety, and dissociation.
Esketamine carries an FDA boxed warning covering sedation, dissociation, respiratory depression, abuse and misuse, among other concerns. Patients receiving Spravato must be monitored in a certified healthcare setting for at least two hours after administration. Access Data
That level of monitoring tells us something important.
This is not a benign wellness treatment.
Ketamine can be addictive
Ketamine is a Schedule III controlled substance.
Its ability to produce dissociation and euphoria creates abuse potential.
This is particularly relevant when ketamine is taken repeatedly at home without close supervision.
Tolerance can develop, and some people escalate their dose or frequency.
That does not mean medically supervised ketamine therapy inevitably causes addiction.
It means screening for substance-use history, dose escalation, craving, and inappropriate use should be part of responsible treatment.
Bladder problems are one of the more distinctive long-term risks
Heavy or prolonged ketamine exposure can damage the urinary tract.
Chronic recreational use has been associated with ketamine-induced cystitis, which can cause urinary urgency, frequency, pelvic pain, painful urination, and—in severe cases—significant bladder and upper urinary tract damage.
This complication is much more strongly associated with frequent recreational use than with short therapeutic courses.
However, it is not irrelevant to medical use.
A 2025 systematic review of psychiatric ketamine studies found urinary symptoms were reported in some treated patients, although they tended to be mild or moderate and were far less severe than those described in chronic recreational users. PubMed
For someone receiving repeated long-term ketamine treatment, new urinary symptoms should not simply be ignored.
Liver and biliary concerns
Frequent exposure has also been associated with abnormalities involving the liver and biliary system.
Reported problems range from elevations in liver enzymes to more significant bile-duct complications in patients with substantial exposure.
These complications are not typical after occasional medically supervised treatment, but they become more relevant as cumulative exposure increases. PubMed
This is another reason indefinite maintenance treatment deserves more scrutiny than a short therapeutic course.
What about cognitive effects?
Acute ketamine clearly impairs attention, judgment, reaction time, and coordination.
That is expected.
The more complicated question is whether repeated long-term treatment affects cognition.
At therapeutic doses, clinical studies have generally been somewhat reassuring, but the long-term evidence remains limited.
Chronic heavy recreational use has been associated with cognitive problems.
So the absence of obvious short-term cognitive toxicity should not be interpreted as proof that frequent lifelong exposure is harmless.
The at-home ketamine issue
One of the areas where I am most cautious is the rapid expansion of compounded ketamine prescribed remotely for home use.
Compounded ketamine can have legitimate medical uses in selected circumstances.
But compounded products are not FDA-approved, meaning the FDA has not evaluated each formulation for safety, effectiveness, quality, or dosing in the same way it evaluates an approved medication.
The FDA has specifically warned about compounded ketamine products being marketed for psychiatric conditions, particularly when treatment occurs without appropriate monitoring for sedation, dissociation, blood-pressure changes, and respiratory complications. U.S. Food and Drug Administration
That concern is not theoretical.
In June 2026, the FDA issued multiple warning letters related to websites selling unapproved ketamine and esketamine products, including products marketed for depression and anxiety. U.S. Food and Drug Administration
The therapeutic evidence for ketamine should not be used to justify poorly monitored ketamine.
Those are two different things.
Is ketamine a psychedelic?
That depends somewhat on terminology.
Ketamine is technically classified as a dissociative anesthetic, not a classic psychedelic like psilocybin or LSD.
Classic psychedelics primarily act through serotonin 5-HT2A receptors.
Ketamine primarily works through the glutamate/NMDA system.
However, at certain doses ketamine can produce profound alterations in perception, self-awareness, time, and consciousness.
So the subjective experience can overlap with what people commonly describe as psychedelic.
From a medical perspective, the pharmacology matters more than the label.
Where does psychotherapy fit?
One of the interesting concepts surrounding ketamine is that the medication may create a temporary period in which the brain becomes more adaptable.
If that is true, what someone does during and after that period may matter.
This has driven interest in combining ketamine with psychotherapy, behavioral change, exercise, sleep optimization, and other interventions.
I think this is a reasonable area of research.
But we should distinguish between what is biologically plausible and what has actually been proven.
We do not yet know the optimal type or timing of psychotherapy around ketamine treatment.
Could ketamine have longevity benefits?
This is where I would be particularly cautious.
There is no evidence that ketamine extends human lifespan.
There is also no evidence that healthy people should take ketamine for anti-aging, neuroprotection, or general longevity.
The neuroplasticity research is interesting, but increased neuroplasticity is not synonymous with slower aging.
Ketamine should not join the list of medications that are marketed as “longevity drugs” simply because they influence an interesting biological pathway.
However, there may be an indirect healthspan argument in selected patients.
Severe depression can affect sleep, exercise, nutrition, social relationships, medication adherence, substance use, employment, and suicide risk.
A patient who successfully treats severe treatment-resistant depression may become more physically active, sleep better, reconnect socially, stop self-medicating with alcohol, and re-engage with preventive medical care.
Those changes could substantially improve someone's overall health trajectory.
In that sense, appropriately treating mental illness is absolutely part of longevity medicine.
The longevity benefit comes from successfully treating the disease, not from ketamine itself being an anti-aging drug.
Neuroplasticity does not automatically equal longevity
This distinction deserves emphasis because it is easy for the wellness industry to blur.
Ketamine can activate signaling pathways associated with BDNF, synaptic formation, and neural plasticity. PubMed
Exercise also promotes neuroplasticity.
Sleep affects neuroplasticity.
Learning affects neuroplasticity.
Psychotherapy can change brain networks.
None of this means that maximally stimulating neuroplasticity will make someone live longer.
Human aging is vastly more complicated.
If anything, ketamine reminds us that a pathway can be beneficial in one context and harmful in another.
A carefully administered dose may help someone with severe depression.
Repeated recreational exposure can damage the bladder, impair cognition, and lead to addiction.
Context and dose matter.
Who might benefit from ketamine?
I think ketamine is most compelling when there is a clear medical problem and a clear therapeutic goal.
For example, someone with severe treatment-resistant depression who has failed multiple conventional treatments may reasonably consider ketamine or esketamine under psychiatric supervision.
Someone with significant depression and acute suicidal thoughts may benefit from rapid-acting treatment as part of a broader psychiatric safety plan.
Selected patients with PTSD or severe refractory pain may also eventually have a role for ketamine after more established treatments have been considered.
That is very different from a healthy person receiving ketamine because it is marketed as a way to “optimize the brain.”
Who needs more caution?
Ketamine deserves particular caution in people with a history of substance-use disorder, poorly controlled hypertension or significant cardiovascular disease, certain psychiatric conditions involving psychosis or mania, significant urinary disease, or situations where reliable supervision and follow-up are not available.
The decision is individualized.
A patient's psychiatric history, medications, substance-use history, cardiovascular status, and treatment setting all matter.
My practical take
Ketamine is one of the more fascinating developments in modern psychiatry.
It has challenged the traditional idea that antidepressants must take weeks to work.
It has also helped shift depression research toward glutamate, neuroplasticity, and synaptic health rather than focusing almost exclusively on serotonin.
For some patients with severe treatment-resistant depression, ketamine can be genuinely transformative.
There are also promising signals for anxiety, PTSD, OCD, and selected pain disorders.
But enthusiasm has moved faster than the evidence in some parts of the wellness industry.
Ketamine is still a controlled substance.
The long-term consequences of repeated use remain incompletely understood.
And the proliferation of at-home compounded ketamine should not be confused with the carefully monitored protocols used in much of the clinical research.
From a longevity perspective, I would not recommend ketamine to someone simply because they want better brain health or a longer life.
But I absolutely consider mental health part of longevity.
If ketamine appropriately treats disabling depression, restores function, and allows someone to re-engage with exercise, sleep, relationships, work, and preventive care, that can meaningfully improve healthspan.
That is a much more defensible longevity argument.
Bottom line
Ketamine is an established anesthetic that has emerged as a powerful rapid-acting treatment for certain patients with severe or treatment-resistant depression.
Its effects on glutamate signaling and neuroplasticity make it fundamentally different from conventional antidepressants, and research is expanding into anxiety, PTSD, chronic pain, OCD, and other conditions.
But ketamine also carries real risks, including dissociation, sedation, increases in blood pressure, abuse potential, and—particularly with frequent or prolonged exposure—urinary and hepatobiliary complications. FDA-approved intranasal esketamine therefore requires structured medical supervision, while the FDA continues to caution about inadequately monitored compounded ketamine products. Access Data
Ketamine is not a proven longevity therapy.
Its potential relevance to longevity is more practical: treating severe mental illness may improve the sleep, activity, relationships, substance use, motivation, and overall engagement with health that ultimately shape healthspan.
For the right patient, ketamine may be a very useful medical tool.
It just should not be mistaken for a wellness shortcut.